Muromonab pharmacokinetics

Pharmacokinetics A rapid decrease in T-lymphocytes is observed within a few minutes after administration of Orthoclone OKT3. The volume of distribution of muromonab CD3 is approximately 6.5 liters its half-life is 18 hours. Clinical experience has demonstrated that serum levels greater than or equal to 0.8pg/ml of muromonab CD3 blocks the function of cytotoxic T cells in vitro and in vivo. Reduced T-cell clearance or low plasma... 

Hooks MA, Wade CS, Millikan WJ. 1991. Muromonab CD-3 A review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy. 11 26-37. 

Pharmacodynamics and Pharmacokinetics of mAbs Muromonab CD-3 Pharmacokinetics Basiliximab Pharmacokinetics Trastuzumab Pharmacokinetics Infliximab Pharmacokinetics Rituximab Pharmacokinetics Palivizumab Pharmacokinetics Recommendations for Future Study References... 

---